Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases

"Incyte is a proven leader in the development and commercialization of many important innovative therapies, including a treatment for GVHD.